Northeast Pharmaceutical Group Co., Ltd.

000597.SZ

000597.SZNortheast Pharmaceutical Group Co., Ltd.

Shenzhen

4.13

CNY

-0.09

(-2.13%)

0.27EPS

15.30P/E

5.82BMarket Cap

Oct 25Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

Northeast Pharmaceutical Group Co., Ltd.

000597.SZ

(Shenzhen)

Recent

price

4.13

P/E

ratio

15.3

div

yld

2.37%

ROIC.AI

Legends:

Stock price

Beta (1.0 Market)

% total return 09/10

Stock

S&P500

-18.06

21.84

-23.52

22.67

-26.90

83.28

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
6.73	6.89	6.51	5.23	4.3	5.22	4.93	3.64	4.56	5.37	6.16	6.14	6.02	5.76	6.29	5.75	5.49	Revenue per Share
0.52	0.64	0.07	-0.53	0.01	-0.23	0.1	-0.36	0.02	0.11	0.16	0.13	0.01	0.07	0.25	0.25	0.26	Basic EPS, GAAP
0.51	-0.33	-0.29	-0.88	-0.1	-0.97	-0.55	-0.23	0.2	-0.68	-0.23	0.09	0.14	0.44	0.62	0.25	-0.15	Free Cash Flow per Basic Share
0.19	0.17	0.22	0.19	0.2	0.26	0.23	0.17	0.15	0.15	0.14	0.1	0.1	0.12	0.08	0.15	0.13	Dividend per Share
1.03	1.5	1.52	0.98	0.82	0.77	0.91	0.39	0.41	0.52	0.68	0.98	1.44	1.3	1.6	1.7	1.7	Book Value per Share
1.78	1.64	1.64	1.16	1.02	1.09	2.23	1.48	1.48	1.51	2.23	2.22	2.57	2.34	2.75	3	3.04	Tangible Book Value per Share
685	739	742	742	900	741	879	1,053	1,056	1,057	1,212	1,338	1,226	1,415	1,401	1,434	1,441	Basic Weighted Avg Shares
4,610	5,095	4,828	3,883	3,865	3,871	4,333	3,834	4,814	5,676	7,467	8,220	7,384	8,145	8,809	8,243	7,905	Sales/Revenue/Turnover
18.54	12.81	3.69	-8.11	-4.15	-0.85	4.25	-5.13	4.06	6.44	6.32	5.45	4.41	4.37	5.15	7.84	9.05	Operating Margin (%)
105	128	190	218	159	148	171	213	317	326	323	340	481	551	561	575	- -	Depreciation Expense
358	476	53	-394	8	-167	87	-384	24	119	195	174	12	99	350	358	380	Net Income, GAAP
28.37	18.53	28.84	- -	87.22	- -	20.74	- -	29.61	9.9	5.79	23.99	88.21	20.57	32.03	22.98	30.52	Effective Tax Rate (%)
7.76	9.35	1.11	-10.15	0.21	-4.31	2.01	-10.02	0.49	2.1	2.61	2.12	0.17	1.22	3.98	4.35	4.81	Profit Margin (%)
111	898	1,000	-378	-763	-786	-275	-733	106	-469	-1,064	-2,020	-1,772	-1,399	-493	215	404	Working Capital
6	1,011	1,163	609	609	100	100	180	600	235	874	150	256	218	256	181	98	LT Debt
1,575	2,048	2,074	1,742	1,750	1,599	2,761	2,401	2,434	2,548	3,588	3,918	4,122	4,290	4,713	5,159	5,209	Total Equity
24.16	14.54	3.03	- -	-0.48	- -	2.84	- -	2.44	5.56	6.6	4.57	0.51	3.79	4.35	7.16	6.93	Return on Invested Capital (%)
21.46	18.37	3.74	- -	0.81	- -	5.65	- -	3.14	6.62	7.16	5.35	0.52	3.64	8.11	8.49	8.68	Return on Capital (%)
66.53	52.46	4.78	-42.58	1.11	-25.62	12.77	-63.65	5.62	24.04	28.38	16.34	0.8	5.49	17.15	15.31	16.23	Return on Common Equity (%)

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	8.74%	2.39%	-6.42%
Net Income, GAAP	52.47%	172.03%	2.34%
Free Cash Flow	-63.15%	28.05%	-59.36%
Total Cash Common Dividend	6.16%	14.59%	100.79%
Total Equity	14.43%	7.56%	9.45%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Business: Northeast Pharmaceutical Group Co., Ltd. provides chemical synthetic and bio-fermentation APIs, and medicinal and micro-ecological preparation products in China. It offers various nutritional products, such as Vitamin C, L-Carnitine, and other products; API products comprising fosfomycin, anti-aids, and other products; and chemical products, including chemical and pharmaceutical intermediates, chiral separation reagent products, etc. The company also provides digestives, narcotic medicines, cardiovascular, cerebrovascular medicines, etc. In addition, it engages in medical distribution business. Northeast Pharmaceutical Group Co., Ltd. was founded in 1993 and is based in Shenyang, China.

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
6.73	6.89	6.51	5.23	4.3	5.22	4.93	3.64	4.56	5.37	6.16	6.14	6.02	5.76	6.29	5.75	5.49	Revenue per Share
0.52	0.64	0.07	-0.53	0.01	-0.23	0.1	-0.36	0.02	0.11	0.16	0.13	0.01	0.07	0.25	0.25	0.26	Basic EPS, GAAP
0.51	-0.33	-0.29	-0.88	-0.1	-0.97	-0.55	-0.23	0.2	-0.68	-0.23	0.09	0.14	0.44	0.62	0.25	-0.15	Free Cash Flow per Basic Share
0.19	0.17	0.22	0.19	0.2	0.26	0.23	0.17	0.15	0.15	0.14	0.1	0.1	0.12	0.08	0.15	0.13	Dividend per Share
1.03	1.5	1.52	0.98	0.82	0.77	0.91	0.39	0.41	0.52	0.68	0.98	1.44	1.3	1.6	1.7	1.7	Book Value per Share
1.78	1.64	1.64	1.16	1.02	1.09	2.23	1.48	1.48	1.51	2.23	2.22	2.57	2.34	2.75	3	3.04	Tangible Book Value per Share
685	739	742	742	900	741	879	1,053	1,056	1,057	1,212	1,338	1,226	1,415	1,401	1,434	1,441	Basic Weighted Avg Shares
4,610	5,095	4,828	3,883	3,865	3,871	4,333	3,834	4,814	5,676	7,467	8,220	7,384	8,145	8,809	8,243	7,905	Sales/Revenue/Turnover
18.54	12.81	3.69	-8.11	-4.15	-0.85	4.25	-5.13	4.06	6.44	6.32	5.45	4.41	4.37	5.15	7.84	9.05	Operating Margin (%)
105	128	190	218	159	148	171	213	317	326	323	340	481	551	561	575	- -	Depreciation Expense
358	476	53	-394	8	-167	87	-384	24	119	195	174	12	99	350	358	380	Net Income, GAAP
28.37	18.53	28.84	- -	87.22	- -	20.74	- -	29.61	9.9	5.79	23.99	88.21	20.57	32.03	22.98	30.52	Effective Tax Rate (%)
7.76	9.35	1.11	-10.15	0.21	-4.31	2.01	-10.02	0.49	2.1	2.61	2.12	0.17	1.22	3.98	4.35	4.81	Profit Margin (%)
111	898	1,000	-378	-763	-786	-275	-733	106	-469	-1,064	-2,020	-1,772	-1,399	-493	215	404	Working Capital
6	1,011	1,163	609	609	100	100	180	600	235	874	150	256	218	256	181	98	LT Debt
1,575	2,048	2,074	1,742	1,750	1,599	2,761	2,401	2,434	2,548	3,588	3,918	4,122	4,290	4,713	5,159	5,209	Total Equity
24.16	14.54	3.03	- -	-0.48	- -	2.84	- -	2.44	5.56	6.6	4.57	0.51	3.79	4.35	7.16	6.93	Return on Invested Capital (%)
21.46	18.37	3.74	- -	0.81	- -	5.65	- -	3.14	6.62	7.16	5.35	0.52	3.64	8.11	8.49	8.68	Return on Capital (%)
66.53	52.46	4.78	-42.58	1.11	-25.62	12.77	-63.65	5.62	24.04	28.38	16.34	0.8	5.49	17.15	15.31	16.23	Return on Common Equity (%)

	Dec'23	Mar'24	Jun'24
Total Current Assets	9,783	10,257	9,429
Accounts Receivable, Net	1,814	2,017	2,270
Cash, Cash Equivalents & STI	5,651	5,818	4,892
Inventories	1,364	1,433	1,404
Total Current Liabilities	9,568	9,915	9,025
Payables & Accruals	- -	- -	- -
ST Debt	2,037	2,314	2,221
Deferred Revenue	- -	- -	- -

	Dec'23	Mar'24	Jun'24
ST Debt	2,037	2,314	2,221
LT Borrowings	150	78	78
LT Finance Leases	31	22	19
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	1,429	1,429	1,429
Market Capitalization	7,491	6,729	5,576

Year	Q1	Q2	Q3	Q4	FY
2022	2,353	2,067	2,149	2,240	8,809
2023	2,354	2,152	1,898	1,839	8,243
2024	1,940	2,228	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	0.05	- -	- -	- -	0.25
2023	0.05	- -	- -	- -	0.25
2024	0.04	- -	- -	- -	- -

Northeast Pharmaceutical Group Co., Ltd.

Growth Rates

(avg. rate of change)

Growth Rates

(avg. rate of change)

Working Capital

Capital Structure

Quarterly Earnings Per Share

Year

Quarterly Revenue

Year

Quarterly Dividends Per Share

Year